These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 37271923)
1. Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders. Feng L; Chao J; Ye P; Luong Q; Sun G; Liu W; Cui Q; Flores S; Jackson N; Shayento ANH; Sun G; Liu Z; Hu W; Shi Y Adv Sci (Weinh); 2023 Aug; 10(23):e2206910. PubMed ID: 37271923 [TBL] [Abstract][Full Text] [Related]
2. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs. Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759 [TBL] [Abstract][Full Text] [Related]
3. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
5. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
6. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
7. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism. Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081 [TBL] [Abstract][Full Text] [Related]
8. The Journey of iPSC-derived OPCs in Demyelinating Disorders: From Lohrasbi F; Ghasemi-Kasman M; Soghli N; Ghazvini S; Vaziri Z; Abdi S; Darban YM Curr Neuropharmacol; 2023; 21(9):1980-1991. PubMed ID: 36825702 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases shape the oligodendrocyte (niche) during development and upon demyelination. Gorter RP; Baron W Neurosci Lett; 2020 Jun; 729():134980. PubMed ID: 32315713 [TBL] [Abstract][Full Text] [Related]
10. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
11. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice. Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133 [TBL] [Abstract][Full Text] [Related]
12. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282 [TBL] [Abstract][Full Text] [Related]
13. Loss of Tuberous Sclerosis Complex1 in Adult Oligodendrocyte Progenitor Cells Enhances Axon Remyelination and Increases Myelin Thickness after a Focal Demyelination. McLane LE; Bourne JN; Evangelou AV; Khandker L; Macklin WB; Wood TL J Neurosci; 2017 Aug; 37(31):7534-7546. PubMed ID: 28694334 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type Chao J; Feng L; Ye P; Chen X; Cui Q; Sun G; Zhou T; Tian E; Li W; Hu W; Riggs AD; Matalon R; Shi Y iScience; 2022 Jun; 25(6):104391. PubMed ID: 35637731 [TBL] [Abstract][Full Text] [Related]
16. Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Elitt MS; Shick HE; Madhavan M; Allan KC; Clayton BLL; Weng C; Miller TE; Factor DC; Barbar L; Nawash BS; Nevin ZS; Lager AM; Li Y; Jin F; Adams DJ; Tesar PJ Stem Cell Reports; 2018 Sep; 11(3):711-726. PubMed ID: 30146490 [TBL] [Abstract][Full Text] [Related]
17. Temporal and partial inhibition of GLI1 in neural stem cells (NSCs) results in the early maturation of NSC derived oligodendrocytes in vitro. Namchaiw P; Wen H; Mayrhofer F; Chechneva O; Biswas S; Deng W Stem Cell Res Ther; 2019 Aug; 10(1):272. PubMed ID: 31455382 [TBL] [Abstract][Full Text] [Related]
18. Canavan disease: a white matter disorder. Kumar S; Mattan NS; de Vellis J Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907 [TBL] [Abstract][Full Text] [Related]
19. Conditional Deletion of the L-Type Calcium Channel Cav1.2 in NG2-Positive Cells Impairs Remyelination in Mice. Santiago González DA; Cheli VT; Zamora NN; Lama TN; Spreuer V; Murphy GG; Paez PM J Neurosci; 2017 Oct; 37(42):10038-10051. PubMed ID: 28899915 [TBL] [Abstract][Full Text] [Related]
20. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Wang S; Bates J; Li X; Schanz S; Chandler-Militello D; Levine C; Maherali N; Studer L; Hochedlinger K; Windrem M; Goldman SA Cell Stem Cell; 2013 Feb; 12(2):252-64. PubMed ID: 23395447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]